Group working in lab

Why Strathclyde?Women in Science

Here are some of our amazing Strathclyde Women in Science who are all working towards different goals and achievements across the sector.

Rabinder Buttar

“On International Day of Women and Girls in Science, I acknowledge all women in science who improve healthcare, develop innovative medicines and ultimately save patients' lives. My PhD in immunology inspired me to join the pharmaceutical industry and gain experience in clinical research which then led me to build my own multi award winning entrepreneurial global company Clintec which now is part of IQVIA - one of the World's Most Admired companies (Fortune 500). I encourage all women to be confident and reach for the stars!"

Dr Rabinder Buttar

Global Entrepreneur, Former Founder, President & CEO Clintec International Ltd, an IQVIA company

More about Dr Rabinder's journey
Carolina Wani, Digital Health Systems

"At Strathclyde, the course has been everything I hoped it would be. It’s fast-paced and it’s innovative. At times it’s forced me to delve into my creative energy. You’re going into unknown areas. One of the first things I did on the course was to create a prototype app for people with rheumatoid arthritis in their hands."

Lisa McCann & Roma Maguire, Computer & Information Sciences

"The eSMART study is a European randomised controlled trial in five countries across Europe of our mobile phone-based remote patient monitoring system to support patients with cancer during their chemotherapy treatment."

Vivien Mitchell
I have been very lucky to have had the opportunity to work in clinical trials for over 20 years. To play a small part in the drug development process; to help improve, change and save lives is a very great privilege.
Vivien Mitchell
Senior Director at a drug development company
Christine Dufés, Strathclyde Institute of Pharmacy & Biomedical Science

"We've developed some new seek-and-destroy nanomedicines...and we've demonstrated that intravenous administration of this nanomedicine led to the complete disappearance of 70% of one type of [prostate cancer] tumour, and 50% of another type of [prostate cancer] tumour."

Reshma Ranjit, Cancer Therapies (MSc)

"Cancer was the course I always wanted to do. It includes care-targeted therapies and advanced biomedical research labs and quite a few new subjects which are included are drug discovery and targeted therapies."

Our staff